Understanding how heat shock factors help cells cope with stress
Regulation and interplay of Heat Shock Factors in growth-associated proteotoxic stresses
This study is looking at how a special protein called Heat Shock Factor 1 helps keep other proteins healthy in our cells, especially when they’re under stress like in cancer, and it hopes to find new ways to improve treatments for patients by understanding how cancer cells cope with this stress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10897302 on NIH RePORTER |
What this research studies
This research investigates the role of heat shock factors, particularly Heat Shock Factor 1 (HSF1), in maintaining protein health within cells, especially under stress conditions like cancer. It explores how HSF1 not only helps in protein folding but also regulates various cellular processes that are crucial for cell survival and function. By studying these mechanisms, the research aims to uncover new insights into how cells respond to proteotoxic stress, which could lead to novel therapeutic strategies. Patients may benefit from a better understanding of how their cancer cells manage stress and how this knowledge could inform treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit proteotoxic stress and may benefit from therapies targeting heat shock response mechanisms.
Not a fit: Patients with non-cancerous conditions or those whose diseases do not involve proteotoxic stress may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the ability of cells to cope with stress, potentially improving outcomes for cancer patients.
How similar studies have performed: Previous research has shown that targeting heat shock proteins can be beneficial in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mendillo, Marc — Northwestern University at Chicago
- Study coordinator: Mendillo, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.